Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either. I have no interest in any supplier named above.
Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that.
The question about retatrutide mass and identity that I actually want answered is the second one below. The first is context and I have kept it short.
Both are stated with units, and I have said what I already checked so that nobody repeats it.
On identity confirmation more generally: for a compound with no widely available reference material, orthogonal confirmation matters more than usual. A mass result and a chromatographic result together say considerably more than either alone.
Reporting the observation and leaving the explanation open deliberately.
I would be cautious about generalising from the retatrutide mass and identity example above. It is a good example. It is one example.
Post #4 answers the question as asked. The question underneath it is different.
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
I read post #2 twice before replying, because I had assumed the opposite.
Reading this retatrutide mass and identity thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
I have no interest in any supplier named above.
Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.
I have deliberately not rounded that, because the rounding is where the argument starts.
Staff rationale: Hidden by community flags. The substance was fine; the framing attributed motive rather than error, which is R1.
The version of retatrutide mass and identity that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
The corresponding entry is in the public moderation log. Hidden posts are never deleted.
Where I part company with post #6, and it is a narrow parting.
One caution on retatrutide mass and identity: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check.
It is the kind of thing that is obvious once and never again.
Coming back to post #10, because the follow-up matters more than the original answer.
Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.
What I would tell a new member reading about retatrutide mass and identity for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
I read post #13 twice before replying, because I had assumed the opposite.
What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.
That is what the documentation says. What happens in practice is usually close.
Post #17 answers the question as asked. The question underneath it is different.
Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.
Marking that as an opinion rather than a finding.
Post #17 and I disagree about the size of the effect, not about the direction.
Where I would push back on the retatrutide mass and identity consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
Taking post #17 at face value and following it one step further.
Small methodological point on retatrutide mass and identity: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
Answering the question post #21 raises rather than the one it answers.
Reading back through the retatrutide mass and identity threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
Post #22 is the version of this I will quote in future. One addition.
Retatrutide mass and identity is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
Clear enough that I do not think I have a follow-up, which is unusual.
Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present.
That has been true for the cases I have seen and I have not seen many.
Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.
I have changed my mind on this once already, so take it as current rather than settled.
Confirming post #26 from a second method, which matters more than confirming it from a second person.
If someone has run retatrutide mass and identity properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
I had written a reply contradicting post #25 and deleted it. Here is what survived.
Agreed on retatrutide mass and identity, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Retatrutide dose escalation in the published trials
Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…
|
+115 | 125 | 30k | 2y |
|
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper
Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about Retatrutide phase 2 in type that I did…
|
+1 | 5 | 31k | 8mo |
|
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post,…
|
2 | 103 | 17mo | |
|
Second pass at: Retatrutide mass and identity: what a report should show
Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
|
+65 | 71 | 4.6k | 13mo |
|
[2026 update] What we do not know about retatrutide, listed explicitly
What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post, because a question…
|
+79 | 83 | 952 | 11mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
What would change my mind about repair peptides: a specific answer — one year on
What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. Documentation question rather than a…
|
+9 | 13 | 42k | 19mo |
|
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold?
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. The question about Analytical…
|
+28 | 33 | 1.6k | 1mo |
|
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…
|
2 | 52k | 1mo | |
|
What pooling buys you and what it destroys
The question in the title: What pooling buys you and what it destroys I will give what I have already checked below so nobody repeats it. The question about pooling buys that I actually want answered is the…
|
+74 | 83 | 6.6k | 8mo |
|
A well-designed study with a badly written abstract
Posting this under the heading it deserves: A well-designed study with a badly written abstract Everything below is what sits behind that. Reading back through what has been written here about well-designed…
|
+117 | 128 | 7.2k | 14mo |